Goldman Sachs Removes MAKO Surgical from CL-Buy List, Raises PT To $44

September 22, 2011 7:26 AM | 10 seconds read |
Goldman Sachs has removed MAKO Surgical MAKO from the Americas Conviction Buy List but maintains its Buy rating and has raised the price target from $37 to $44.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsGoldman SachsHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!